Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 16.77%104.1M | 25.51%413.17M | 23.21%290.87M | 39.57%198.36M | 71.01%89.15M | 26.46%329.19M | 23.01%236.07M | 16.58%142.12M | -6.33%52.13M | 36.99%260.32M |
Operating revenue | 16.77%104.1M | 25.51%413.17M | 23.21%290.87M | 39.57%198.36M | 71.01%89.15M | 26.46%329.19M | 23.01%236.07M | 16.58%142.12M | -6.33%52.13M | 36.99%260.32M |
Total operating cost | 3.37%92.57M | 12.22%401.54M | 16.68%287.96M | 30.17%194.37M | 34.48%89.55M | 34.44%357.81M | 30.47%246.8M | 25.20%149.32M | 19.63%66.59M | 24.29%266.16M |
Operating cost | 16.71%41.05M | 41.96%170.52M | 47.39%119.86M | 76.41%81.13M | 113.02%35.18M | 49.35%120.12M | 44.03%81.33M | 25.11%45.99M | -3.50%16.51M | 53.50%80.43M |
Operating tax surcharges | 13.37%1.02M | 42.06%3.13M | 54.29%2.69M | 95.64%1.95M | 149.49%902.99K | 75.15%2.2M | 53.59%1.74M | 0.10%996.12K | -29.66%361.93K | 29.60%1.26M |
Operating expense | 11.67%27.37M | 1.43%110.86M | 3.08%80.64M | 10.31%54.84M | 22.84%24.51M | 34.91%109.3M | 38.93%78.23M | 45.72%49.72M | 28.50%19.95M | 14.51%81.02M |
Administration expense | 10.42%11.32M | 4.39%42.64M | 15.13%29.91M | 27.78%19.86M | 37.17%10.25M | 12.92%40.85M | -7.13%25.98M | -9.15%15.54M | 4.83%7.47M | 6.84%36.17M |
Financial expense | -53.87%-1.61M | 49.53%-3.01M | 64.01%-1.68M | 45.06%-1.94M | 9.72%-1.05M | 38.15%-5.97M | 25.80%-4.66M | -19.34%-3.53M | 11.14%-1.16M | -41.05%-9.65M |
-Interest expense (Financial expense) | -59.67%105.68K | -30.18%886.73K | -30.77%712.18K | -26.72%499.43K | -25.57%262.02K | 76.69%1.27M | 127.71%1.03M | 155.89%681.58K | 158.10%352.02K | 55.18%718.74K |
-Interest Income (Financial expense) | 28.56%-1.09M | 39.97%-4.1M | 28.43%-3.6M | 13.75%-2.86M | 5.35%-1.52M | 26.71%-6.83M | 13.02%-5.03M | -6.41%-3.32M | -4.49%-1.61M | -21.66%-9.32M |
Research and development | -32.11%13.42M | -15.23%77.4M | -11.92%56.54M | -5.12%38.52M | -15.73%19.76M | 18.69%91.31M | 19.82%64.19M | 22.15%40.6M | 40.53%23.45M | 22.09%76.93M |
Credit Impairment Loss | 125.69%59.37K | 6.14%-1.27M | 89.19%-143.49K | 85.10%-153.24K | -133.75%-231.06K | -67.70%-1.35M | -1,106.22%-1.33M | -128.69%-1.03M | 1,725.16%684.66K | -292.77%-807.06K |
Asset Impairment Loss | -258.72%-790.52K | -452.23%-2.97M | -70.99%-2.34M | -141.43%-2.11M | -552.64%-220.38K | 23.86%-538.15K | -143.70%-1.37M | -279.00%-872.86K | -253.95%-33.77K | -1.16%-706.8K |
Other net revenue | ||||||||||
Fair value change income | -30.25%2.56M | -6.21%11.43M | 15.74%9.04M | 33.55%6.39M | 6.18%3.67M | 292.42%12.19M | 1,064.29%7.81M | 5,906.97%4.78M | --3.46M | --3.11M |
Invest income | -4.48%1.81M | -11.38%8.98M | -27.91%6.65M | -26.65%4.36M | 7.00%1.89M | 600.15%10.14M | 379.02%9.22M | 403.71%5.94M | 287.80%1.77M | 29.70%-2.03M |
-Including: Investment income associates | -2.33%-508.99K | 55.30%-2.25M | 71.14%-1.16M | 75.62%-796.91K | 66.80%-497.38K | 9.69%-5.04M | 4.25%-4.03M | -14.34%-3.27M | 5.33%-1.5M | -21.22%-5.58M |
Asset deal income | --726.24K | ---33.97K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --22.58K |
Other revenue | 38.72%2.04M | 69.01%26.76M | 180.95%27.84M | 168.11%6.79M | 17.03%1.47M | 70.74%15.83M | 207.72%9.91M | 87.90%2.53M | 79.77%1.26M | -41.98%9.27M |
Operating profit | 190.08%17.93M | 613.11%54.52M | 225.12%43.96M | 363.73%19.27M | 184.38%6.18M | 152.72%7.65M | 404.81%13.52M | 184.50%4.16M | -3,726.12%-7.33M | 125.37%3.03M |
Add:Non operating Income | ---- | 3,636.68%23.66K | 2,342,573.27%23.66K | ---- | ---- | -97.89%633.21 | -100.00%1.01 | -100.00%0.6 | -100.00%0.46 | -56.02%30K |
Less:Non operating expense | -100.00%60 | 18.97%2.42M | 11.87%2.24M | 11.87%2.24M | 0.64%2.01M | 2,334.60%2.04M | --2M | --2M | --2M | -28.42%83.64K |
Total profit | 330.11%17.93M | 829.10%52.13M | 262.35%41.74M | 690.23%17.03M | 144.70%4.17M | 88.78%5.61M | 325.36%11.52M | 44.60%2.16M | -5,675.56%-9.33M | 124.82%2.97M |
Less:Income tax cost | --61.74K | 171.02%55.51K | --15.09K | --20.06K | ---- | 22.03%-78.16K | ---- | ---- | ---- | ---100.23K |
Net profit | 328.63%17.87M | 815.36%52.07M | 262.22%41.73M | 689.30%17.01M | 144.70%4.17M | 85.17%5.69M | 325.36%11.52M | 44.60%2.16M | -5,675.56%-9.33M | 125.66%3.07M |
Net profit from continuing operation | 328.63%17.87M | 815.36%52.07M | 262.22%41.73M | 689.30%17.01M | 144.70%4.17M | 85.17%5.69M | 325.36%11.52M | 44.60%2.16M | -5,675.56%-9.33M | 125.66%3.07M |
Net profit of parent company owners | 328.63%17.87M | 815.36%52.07M | 262.22%41.73M | 689.30%17.01M | 144.70%4.17M | 85.17%5.69M | 325.36%11.52M | 44.60%2.16M | -5,675.56%-9.33M | 125.66%3.07M |
Earning per share | ||||||||||
Basic earning per share | 326.97%0.038 | 814.05%0.1106 | 262.04%0.0887 | 686.96%0.0362 | 144.95%0.0089 | 65.75%0.0121 | 271.21%0.0245 | 24.32%0.0046 | -4,850.00%-0.0198 | 124.41%0.0073 |
Diluted earning per share | 326.97%0.038 | 814.05%0.1106 | 262.04%0.0887 | 686.96%0.0362 | 144.95%0.0089 | 65.75%0.0121 | 271.21%0.0245 | 24.32%0.0046 | -4,850.00%-0.0198 | 124.41%0.0073 |
Other composite income | -1.42K | 1.45K | 522.72 | |||||||
Other composite income of parent company owners | ---1.42K | --1.45K | --522.72 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Total composite income | 328.60%17.87M | 815.39%52.07M | 262.23%41.73M | 689.30%17.01M | 144.70%4.17M | 85.17%5.69M | 325.36%11.52M | 44.60%2.16M | -5,675.56%-9.33M | 125.66%3.07M |
Total composite income of parent company owners | 328.60%17.87M | 815.39%52.07M | 262.23%41.73M | 689.30%17.01M | 144.70%4.17M | 85.17%5.69M | 325.36%11.52M | 44.60%2.16M | -5,675.56%-9.33M | 125.66%3.07M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | -- | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.